A 62-year-old man with a pancreatic mass was referred for endoscopic ultrasound (EUS), which demonstrated infiltration of the portal vein ([Fig. 1]). EUS-guided fine-needle aspiration (FNA) was performed, with no signs of EUS-FNA-related complications. Cytological examination showed only suspicious cells. A second EUS-FNA performed 2 weeks later surprisingly revealed massive inflammation in and around the pancreas ([Fig. 2]). FNA and cytology showed adenocarcinoma and the patient underwent downstaging with combined chemoradiotherapy. After chemoradiotherapy a third EUS examination showed no infiltration of the portal vein. The patient underwent laparoscopy with laparoscopic ultrasound, but resection proved impossible because of the massive inflammatory changes that had been observed on endosonography.
Fig. 1 Endoscopic ultrasound (EUS) image before the EUS-guided fine-needle aspiration (EUS-FNA) showing a 35-mm, echo-poor tumor infiltrating the portal vein.
Fig. 2 EUS 2 weeks after the original EUS-FNA showed diffuse enlargement and an irregular echo pattern covering all of the pancreatic head region. The tumor cannot be differentiated from the inflammation.
EUS-FNA is being used increasingly in the diagnosis and staging of pancreatic tumors, and it is considered to be an accurate and safe procedure [1]
[2]
[3]. Cases of acute pancreatitis following EUS-FNA have been described, but severe cases are rare [3]. There are no previous reports of surgery having to be abandoned as a result of inflammation caused by EUS-FNA, but prolonged surgical procedures due to inflammation caused by percutaneous biopsy of the pancreas has been described [4].
The inflammation seen in this case might have been caused by the preoperative therapy, but in our experience with more than 50 patients who were evaluated after receiving chemoradiotherapy we have not seen any patient with a nonresectable tumor due to inflammation. In addition, the inflammation had already been observed before the chemoradiotherapy was initiated.
In order to evaluate whether the present case was a one-off experience, we reviewed 26 consecutive patients with a nonresectable tumor who underwent downstaging. EUS-FNA was performed in 12 patients. In one of these patients inflammation resulted in prolonged surgery. Pathological examination of the specimen revealed massive fibrosis in and around the pancreas.
We conclude that although EUS-FNA is a safe diagnostic and staging procedure in patients with pancreatic cancer, it is associated with a risk of severe inflammation that can compromise the performance of potentially curative surgery.
Endoscopy_UCTN_Code_CPL_1AL_2AD
